FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate […] ...

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis Pharma AG ...

Today's biotech news covers Pluvicto's prostate cancer play, J&J's big bets on bladder, lung, and talent, and more. Skip to Main Content Manage alerts for this article ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...